Technology ID
TAB-3495
Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery Stable Pharmaceutical Formulation of Propofol Hemisuccinate for Inhalation Delivery
E-Numbers
E-245-2015-0
Lead Inventor
Prabha, Swayam (University of Minnesota)
Co-Inventors
Suryanarayanan, Raj (University of Minnesota)
Gurvich, Vadim (University of Minnesota)
Sadhukha, Tanmoy (University of Minnesota)
Thakral, Seema (University of Minnesota)
Applications
Therapeutics
Therapeutic Areas
Neurology
Lead IC
NCATS
This technology includes a stable pharmaceutical formulation of propofol hemisuccinate for inhalation delivery to treat intractable epilepsy and migraine. The formulation can be used to treat a patient experiencing a seizure aura to prevent a motor seizure. Alternatively, the formulation can be used to treat an epileptic patient who is experiencing seizure clusters in an out-of-hospital or in-hospital setting. For migraines, the formulation can be used to treat a patient experiencing a migraine aura or early migraine to forestall the development of the full symptoms of a migraine headache.
Commercial Applications
Further clinical work could establish the formulation described in this technology for inhalation delivery to treat intractable epilepsy and migraine.
Competitive Advantages
The current formulation is the first available treatment optimized for inhalation delivery for the treatment of both epilepsy and migraine.
Licensing Contact: